drugset / Trial / NCT00975650

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

NCT00975650

Phase 2 Completed 57 enrolled Acerus Pharmaceuticals Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

This clinical trial is being performed to compare the pharmacokinetic profile of testosterone after repeated intra-nasal administration of products of different strengths in subjects with hypogonadism.

Timeline

Start
2009-08
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 5 mg Intranasal
Subject Testosterone Small molecule 8 mg Intranasal
Subject Testosterone Small molecule 11 mg Intranasal
Subject Testosterone Small molecule 14 mg Intranasal

Indications